目的 探讨托法替布所致不良反应（ADR）的发生规律和特点，为临床安全合理用药提供参考。方法 检索中国知网、万方、维普、PubMed、Embase以及Web of Science数据库中有关托法替布ADR的个案报道，并进行数据提取与分析。结果 收集托法替布ADR个案报道13例，其中女性8例，男性5例，年龄多集中在50～59岁。托法替布相关ADR平均发生在用药后1年余，主要以皮肤及其附件损害较多，在停药/减量或对症治疗后好转。结论 托法替布相关ADR多在长期用药后发生，尤其应重视皮肤ADR和感染的防治。临床用药时需要加强用药监测，及时识别，准确处置，确保用药安全。

Objective To investigate the occurrence and characteristics of adverse drug reaction (ADR) caused by tofacitinib and to provide reference for clinical safe and rational drug use. Methods Literature related to ADR case reports of tofacitinib were retrieved from CNKI, Wanfang, VIP, PubMed, Embase, and Web of Science databases, and the data were extracted and analyzed. Results A total of 13 ADR cases of tofacitinib were reported, including 8 females and 5 males, mainly aged between 50 and 59 years old. Tofacitinib-related ADR occurred more than 1 year after medication on average. Skin and accessory damage was the most common primary disease. The cases were improved after drug withdrawal/reduction or symptomatic treatment. Conclusion Tofacitinib-related ADRs usually occurred after long-term administration and attention should be paid to the prevention and treatment of skin ADR and infection. It is necessary to strengthen drug monitoring, timely identification and accurate disposal to ensure drug safety.

R979.5